| Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy E Ravussin, SR Smith, JA Mitchell, R Shringarpure, K Shan, H Maier, ... Obesity 17 (9), 1736-1743, 2009 | 383 | 2009 |
| Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies WJ Sandborn, S Vermeire, L Peyrin-Biroulet, MC Dubinsky, J Panes, ... The Lancet 401 (10383), 1159-1171, 2023 | 361 | 2023 |
| Concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open … AI Guerdjikova, B Walsh, K Shan, AE Halseth, E Dunayevich, SL McElroy Advances in therapy 34 (10), 2307-2315, 2017 | 72 | 2017 |
| Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity A Halseth, K Shan, B Walsh, K Gilder, K Fujioka Obesity 25 (2), 338-345, 2017 | 48 | 2017 |
| Combining regression quantile estimators K Shan, Y Yang Statistica Sinica, 1171-1191, 2009 | 40 | 2009 |
| Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes J Malloy, K Gurney, K Shan, P Yan, S Chen Diabetes, metabolic syndrome and obesity: targets and therapy, 419-424, 2012 | 36 | 2012 |
| Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion A Halseth, K Shan, K Gilder, M Malone, L Acevedo, K Fujioka Obesity Science & Practice 4 (2), 141-152, 2018 | 34 | 2018 |
| Pramlintide improved measures of glycemic control and body weight in patients with type I diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy K Herrmann, JP Frias, SV Edelman, K Lutz, K Shan, S Chen, D Maggs, ... Postgraduate medicine 125 (3), 136-144, 2013 | 30 | 2013 |
| 968a: etrasimod 2 mg once daily as treatment for moderately to severely active ulcerative colitis: results from the phase 3 elevate Uc 52 and elevate Uc 12 trials WJ Sandborn, S Vermeire, L Peyrin-Biroulet, MC Dubinsky, J Panes, ... Gastroenterology 162 (7), 1395, 2022 | 15 | 2022 |
| Generative artificial intelligence versus clinicians: Who diagnoses multiple sclerosis faster and with greater accuracy? MA Patel, F Villalobos, K Shan, LM Tardo, LA Horton, PV Sguigna, ... Multiple sclerosis and related disorders 90, 105791, 2024 | 12 | 2024 |
| P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials S Vermeire, L Peyrin-Biroulet, J Panés, M Regueiro, PG Kotze, ... Journal of Crohn's and Colitis 17 (Supplement_1), i619-i620, 2023 | 12 | 2023 |
| Association of blood pressure with brain white matter microstructural integrity assessed with MRI diffusion tensor imaging in healthy young adults J Won, P Maillard, K Shan, J Ashley, D Cardim, DC Zhu, R Zhang Hypertension 81 (5), 1145-1155, 2024 | 10 | 2024 |
| Impact of prior biologic or janus kinase inhibitor therapy on efficacy and safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 trials S Vermeire, BE Sands, L Peyrin-Biroulet, GR D’Haens, J Panés, AJ Yarur, ... Journal of Crohn's and Colitis 18 (11), 1780-1794, 2024 | 9 | 2024 |
| Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009; 17: 1736-1743 E Ravussin, SR Smith, JA Mitchell, R Shringarpure, K Shan, H Maier, ... Přejít k původnímu zdroji... Přejít na PubMed, 2009 | 9 | 2009 |
| Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles K Herrmann, K Shan, SC Brunell, S Chen Endocrine practice 20 (10), 1070-1075, 2014 | 8 | 2014 |
| Associations of central arterial stiffness with brain white matter integrity and gray matter volume in MRI across the adult lifespan J Won, T Tomoto, K Shan, T Tarumi, R Zhang Journal of Magnetic Resonance Imaging, 2025 | 6 | 2025 |
| P207 Effects of fluconazole, gemfibrozil, and rifampin on the pharmacokinetics, safety, and tolerability of etrasimod C Lee, C Taylor, Y Tang, L Villa-Caballero, K Shan, A Randle, JS Grundy Gut 71 (Suppl 1), A142-A142, 2022 | 5 | 2022 |
| Faster and better than a physician?: Assessing diagnostic proficiency of ChatGPT in misdiagnosed individuals with neuromyelitis optica spectrum disorder K Shan, MA Patel, M McCreary, TG Punnen, F Villalobos, LM Tardo, ... Journal of the Neurological Sciences 468, 123360, 2025 | 4 | 2025 |
| Tu1731 EFFICACY OF ETRASIMOD ON SYMPTOMATIC RELIEF IN PATIENTS WITH ULCERATIVE COLITIS: AN ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS M Chaparro, A Armuzzi, PM Irving, M Allez, MC Dubinsky, BE Sands, ... Gastroenterology 164 (6), S-1099-S-1100, 2023 | 4* | 2023 |
| A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the … C Lee, A Ramaiya, Y Tang, A Sapone, K Shan, A Randle, J Grundy JOURNAL OF CROHNS & COLITIS 16, I029-I029, 2022 | 4 | 2022 |
